CRBP insider transaction filings
Corbus Pharmaceuticals Holdings, Inc. — 41 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-17. Screen CRBP transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-17 | 4 | Nicacio Leonardo Viana — Chief Medical Officer | Grant/award (A): 58,333 @ $0 · Grant/award (A): 191,676 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4 | Saxena Nishant C — Chief Business Officer | Purchase (P): 2,600 @ $9.63 | EDGAR |
| 2026-08-10 | 4 | Moran Sean F. — Chief Financial Officer | Sale (S): 12,000 @ $10.08 | EDGAR |
| 2026-08-10 | 4 | Cohen Yuval — Chief Executive Officer, Director | Sale (S): 17,000 @ $10.08 | EDGAR |
| 2026-06-11 | 4 | Kung Winston — Director | Sale (S): 2,026 @ $7.91 | EDGAR |
| 2026-06-11 | 4 | Jenkins John Kenneth — Director | Sale (S): 4,800 @ $7.91 | EDGAR |
| 2026-06-11 | 4 | Altmeyer Anne — Director | Sale (S): 2,412 @ $7.91 | EDGAR |
| 2026-06-03 | 4 | Saxena Nishant C — Chief Business Officer | Purchase (P): 4,500 @ $7.33 · Purchase (P): 9,000 @ $7.58 | EDGAR |
| 2026-05-22 | 4 | Saxena Nishant C — Chief Business Officer | Grant/award (A): 58,300 @ $0 · Grant/award (A): 192,300 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Kung Winston — Director | Grant/award (A): 3,800 @ $0 · Grant/award (A): 12,300 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Jacques Rachelle Suzanne — Director | Grant/award (A): 3,800 @ $0 · Grant/award (A): 12,300 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Jenkins John Kenneth — Director | Grant/award (A): 3,800 @ $0 · Grant/award (A): 12,300 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Altmeyer Anne — Director | Grant/award (A): 3,800 @ $0 · Grant/award (A): 12,300 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Ben Yong — Director | Grant/award (A): 3,800 @ $0 · Grant/award (A): 12,300 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Pfeiffenberger Brent — Director | Grant/award (A): 7,500 @ $0 · Grant/award (A): 24,700 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Smethurst Dominic — Chief Medical Officer | Sale (S): 6,097 @ $8.30 | EDGAR |
| 2026-02-18 | 4 | Hodgson Ian — Chief Operating Officer | Sale (S): 847 @ $7.38 | EDGAR |
| 2026-02-18 | 4 | Cohen Yuval — Chief Executive Officer, Director | Sale (S): 13,871 @ $7.78 | EDGAR |
| 2026-02-18 | 4 | Moran Sean F. — Chief Financial Officer | Sale (S): 4,701 @ $7.78 | EDGAR |
| 2026-02-04 | 4 | Smethurst Dominic — Chief Medical Officer | Sale (S): 3,285 @ $8.09 | EDGAR |
| 2026-02-04 | 4 | Hodgson Ian — Chief Operating Officer | Sale (S): 2,415 @ $8.09 | EDGAR |
| 2026-01-16 | 4 | Hodgson Ian — Chief Operating Officer | Grant/award (A): 28,365 @ $0 · Grant/award (A): 85,095 (derivative) @ $0 | EDGAR |
| 2026-01-16 | 4 | Smethurst Dominic — Chief Medical Officer | Grant/award (A): 28,365 @ $0 · Grant/award (A): 85,095 (derivative) @ $0 | EDGAR |
| 2026-01-16 | 4 | Cohen Yuval — Chief Executive Officer, Director | Grant/award (A): 50,000 @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2026-01-16 | 4 | Moran Sean F. — Chief Financial Officer | Grant/award (A): 28,082 @ $0 · Grant/award (A): 84,247 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | Cormorant Asset Management, LP — 10% owner Cormorant Global Healthcare Master Fund, LP — 10% owner Chen Bihua — 10% owner | Sale (S): 30,029 @ $11.46 | EDGAR |
| 2025-10-27 | 4 | Cohen Yuval — Chief Executive Officer, Director | Option exercise (M): 18,660 @ $4.26 · Sale (S): 18,660 @ $17.01 · Option exercise (M): 8,973 @ $4.26 · Sale (S): 8,973 @ $17.14 · Option exercise (M): 18,660 (derivative) @ $0 · Option exercise (M): 8,973 (derivative) @ $0 | EDGAR |
| 2025-10-27 | 4 | Moran Sean F. — Chief Financial Officer | Option exercise (M): 12,981 @ $4.26 · Sale (S): 12,981 @ $17.02 · Option exercise (M): 12,981 (derivative) @ $0 | EDGAR |
| 2025-10-21 | 4 | Altmeyer Anne — Director | Option exercise (M): 1,060 @ $4.80 · Sale (S): 1,060 @ $20.50 · Option exercise (M): 1,060 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Kung Winston — Director | Grant/award (A): 4,800 @ $0 · Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Ben Yong — Director | Grant/award (A): 4,800 @ $0 · Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Jenkins John Kenneth — Director | Sale (S): 2,783 @ $7.35 · Grant/award (A): 4,800 @ $0 · Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Altmeyer Anne — Director | Sale (S): 1,392 @ $7.25 · Grant/award (A): 4,800 @ $0 · Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Jacques Rachelle Suzanne — Director | Grant/award (A): 4,800 @ $0 · Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | HOLMER ALAN F — Director | Grant/award (A): 4,800 @ $0 · Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | Smethurst Dominic — Chief Medical Officer | Sale (S): 6,393 @ $6.78 | EDGAR |
| 2025-02-18 | 4 | Cohen Yuval — Chief Executive Officer, Director | Sale (S): 7,134 @ $8.76 | EDGAR |
| 2025-02-18 | 4 | Moran Sean F. — Chief Financial Officer | Sale (S): 2,792 @ $8.76 | EDGAR |
| 2025-02-04 | 4 | Smethurst Dominic — Chief Medical Officer | Grant/award (A): 27,200 @ $0 · Grant/award (A): 91,200 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Cohen Yuval — Chief Executive Officer, Director | Grant/award (A): 68,100 @ $0 · Grant/award (A): 228,800 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Moran Sean F. — Chief Financial Officer | Grant/award (A): 27,500 @ $0 · Grant/award (A): 92,500 (derivative) @ $0 | EDGAR |
Recent 8-K events — Corbus Pharmaceuticals Holdings, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-26 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-14 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-07 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CRBP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →